![Page 1: Conclusions & Recommendations 24 th IEAG March 2012](https://reader033.vdocuments.us/reader033/viewer/2022052414/56649e395503460f94b29ec7/html5/thumbnails/1.jpg)
Conclusions & Recommendations
24th IEAG
March 2012
![Page 2: Conclusions & Recommendations 24 th IEAG March 2012](https://reader033.vdocuments.us/reader033/viewer/2022052414/56649e395503460f94b29ec7/html5/thumbnails/2.jpg)
2010*
* data as on 30 October 2010
Last detected case January 2011
Context – a polio free India!
No WPV from any source since January 2011
India is no longer an endemic country!
![Page 3: Conclusions & Recommendations 24 th IEAG March 2012](https://reader033.vdocuments.us/reader033/viewer/2022052414/56649e395503460f94b29ec7/html5/thumbnails/3.jpg)
But risks remain……
![Page 4: Conclusions & Recommendations 24 th IEAG March 2012](https://reader033.vdocuments.us/reader033/viewer/2022052414/56649e395503460f94b29ec7/html5/thumbnails/4.jpg)
Questions to the IEAG
• What are the challenges that India is likely to face in maintaining polio-free status?
• What lessons from other countries can be applied in India to protect the programme gains?
• What strategies should India follow in 2012-2014 to sustain polio-free status?
• Is isolation of VDPVs a concern for India?
• How should India plan for the polio endgame strategy?
![Page 5: Conclusions & Recommendations 24 th IEAG March 2012](https://reader033.vdocuments.us/reader033/viewer/2022052414/56649e395503460f94b29ec7/html5/thumbnails/5.jpg)
Risks
• Importing WPV
• Development of cVDPVs
![Page 6: Conclusions & Recommendations 24 th IEAG March 2012](https://reader033.vdocuments.us/reader033/viewer/2022052414/56649e395503460f94b29ec7/html5/thumbnails/6.jpg)
Lessons
• Its not over until its over everywhere
• 'The price of freedom is eternal vigilance'
![Page 7: Conclusions & Recommendations 24 th IEAG March 2012](https://reader033.vdocuments.us/reader033/viewer/2022052414/56649e395503460f94b29ec7/html5/thumbnails/7.jpg)
Challenges• Maintaining immunity• Maintaining surveillance• Readiness to respond• Reducing risk• Building on polio• Preparing for the endgame
![Page 8: Conclusions & Recommendations 24 th IEAG March 2012](https://reader033.vdocuments.us/reader033/viewer/2022052414/56649e395503460f94b29ec7/html5/thumbnails/8.jpg)
Maintaining immunity
![Page 9: Conclusions & Recommendations 24 th IEAG March 2012](https://reader033.vdocuments.us/reader033/viewer/2022052414/56649e395503460f94b29ec7/html5/thumbnails/9.jpg)
• Maintain high levels of immunity
especially in high risk areas and
populations
• Protect against both WPV & VDPVs
Objectives of SIA strategy
![Page 10: Conclusions & Recommendations 24 th IEAG March 2012](https://reader033.vdocuments.us/reader033/viewer/2022052414/56649e395503460f94b29ec7/html5/thumbnails/10.jpg)
Recommended SIA calendar, 2012
conducted planned
NID with tOPV SNID with bOPV
![Page 11: Conclusions & Recommendations 24 th IEAG March 2012](https://reader033.vdocuments.us/reader033/viewer/2022052414/56649e395503460f94b29ec7/html5/thumbnails/11.jpg)
Recommended SIAs, 2013-14NID with tOPV SNID with bOPV
2013
2014
![Page 12: Conclusions & Recommendations 24 th IEAG March 2012](https://reader033.vdocuments.us/reader033/viewer/2022052414/56649e395503460f94b29ec7/html5/thumbnails/12.jpg)
Maintaining surveillance
![Page 13: Conclusions & Recommendations 24 th IEAG March 2012](https://reader033.vdocuments.us/reader033/viewer/2022052414/56649e395503460f94b29ec7/html5/thumbnails/13.jpg)
14.3 86%
Non-polio AFP rate Stool collection rate
Surveillance performance indicators, last 6 months
IndiaLess than 60%60% to 69%70% to 79%80% and aboveNo AFP case
# AFP cases, Jan – Feb
![Page 14: Conclusions & Recommendations 24 th IEAG March 2012](https://reader033.vdocuments.us/reader033/viewer/2022052414/56649e395503460f94b29ec7/html5/thumbnails/14.jpg)
• Expand environmental surveillance: Punjab & Gujarat
• Conduct planned field reviews & act on gaps– urgently address the issues identified in Andhra Pradesh
• Involve district / block level government staff in all components of AFP surveillance– response to AFP case reporting, sensitization of the existing
reporting network, regular review of surveillance database etc
• Laboratory human and financial resources should be ensured to maintain high performance
Recommendations: Surveillance
![Page 15: Conclusions & Recommendations 24 th IEAG March 2012](https://reader033.vdocuments.us/reader033/viewer/2022052414/56649e395503460f94b29ec7/html5/thumbnails/15.jpg)
Readiness to respond
![Page 16: Conclusions & Recommendations 24 th IEAG March 2012](https://reader033.vdocuments.us/reader033/viewer/2022052414/56649e395503460f94b29ec7/html5/thumbnails/16.jpg)
Recommendations: Response
• The new state EPRPs should be reviewed and evaluated by GOI and partners by the end of April 2012
• National & state EPRPs should be updated at minimum annually – updates must include a full new risk analysis to
inform risk mitigation measures.
• Conduct simulations of the emergency response plans at national and state levels
![Page 17: Conclusions & Recommendations 24 th IEAG March 2012](https://reader033.vdocuments.us/reader033/viewer/2022052414/56649e395503460f94b29ec7/html5/thumbnails/17.jpg)
Recommendations: Planning for response
• State EPRPs must adequately address: – Plans for overcoming staff vacancies in high risk areas;– Systematic inclusion of high risk areas & populations for
RI strengthening;– Timeline for harmonization of SIA and RI microplans in
high risk areas; – Assignment of HR districts to Rapid Response Team
members (RRT) for regular review of RI, SIA and emergency preparedness;
– Assessment of communication risks and social mapping;
– Identification of media spokesperson; – Plans for procurement of logistics and IEC materials for
undertaking urgent mop-ups.
![Page 18: Conclusions & Recommendations 24 th IEAG March 2012](https://reader033.vdocuments.us/reader033/viewer/2022052414/56649e395503460f94b29ec7/html5/thumbnails/18.jpg)
Reducing risk
![Page 19: Conclusions & Recommendations 24 th IEAG March 2012](https://reader033.vdocuments.us/reader033/viewer/2022052414/56649e395503460f94b29ec7/html5/thumbnails/19.jpg)
Recommendations: Communications
• Maintain SMNet and other ground-level initiatives (e.g. through ASHA & Anganwari Workers) in traditional polio reservoirs and in newly emerging high-risk areas until risk is gone
• Appropriate social network research should be carried out in key high risk areas to inform programme actions
• Document and share experience & best practices, including elements of the SMNet, media engagement and utilization of data for identification, tracking and engagement of high-risk populations
• All communication efforts, including SMNet, at all levels adopt promotion of routine immunization as a primary message in all public communication
![Page 20: Conclusions & Recommendations 24 th IEAG March 2012](https://reader033.vdocuments.us/reader033/viewer/2022052414/56649e395503460f94b29ec7/html5/thumbnails/20.jpg)
Recommendations: OPV supply
• All pre-qualified global OPV producers not yet licensed in India should be encouraged to apply for & complete the licensing process
• Considering the risks to vaccine supply DCGI should fast track the licensing process for already pre-qualified vaccines.
• GoI should continue to ensure a 50 million dose rolling emergency stock (40 million bOPV & 10 million tOPV) to enable rapid response
• GoI should plan for a 24 month time frame for OPV procurement
• To facilitate timely procurement of OPV for SIAs only– the standard vaccine shelf life can be reduced to 60% – the requirement for primary vaccine vial packaging indicating the product is not
for sale be waivered (still required for secondary and outer packaging)
![Page 21: Conclusions & Recommendations 24 th IEAG March 2012](https://reader033.vdocuments.us/reader033/viewer/2022052414/56649e395503460f94b29ec7/html5/thumbnails/21.jpg)
Reducing risk - importation
• Immunization of travellers at border crossing points should continue until there is no longer an epidemiological risk.
• Particular attention should continue to be paid to border populations to ensure that they are effectively covered by SIAs and routine immunization.
![Page 22: Conclusions & Recommendations 24 th IEAG March 2012](https://reader033.vdocuments.us/reader033/viewer/2022052414/56649e395503460f94b29ec7/html5/thumbnails/22.jpg)
Reducing risk - VDPVs
• All detected VDPVs should continue to be thoroughly and rapidly investigated to determine risk of circulation
• Any evidence of circulation - mop-up response!
![Page 23: Conclusions & Recommendations 24 th IEAG March 2012](https://reader033.vdocuments.us/reader033/viewer/2022052414/56649e395503460f94b29ec7/html5/thumbnails/23.jpg)
Building on polio
![Page 24: Conclusions & Recommendations 24 th IEAG March 2012](https://reader033.vdocuments.us/reader033/viewer/2022052414/56649e395503460f94b29ec7/html5/thumbnails/24.jpg)
Data not available
Below 5 %
5 % - 10 %
>10 % - 25%
>25 %
Where are we missing the maximum number of children?
69% of partially and un-immunized children in 6 states:•Uttar Pradesh •Bihar•Madhya Pradesh, •Rajasthan •West Bengal•Jharkhand
Source: CES 2009; Full immunization of children surveyed 12-23 months
![Page 25: Conclusions & Recommendations 24 th IEAG March 2012](https://reader033.vdocuments.us/reader033/viewer/2022052414/56649e395503460f94b29ec7/html5/thumbnails/25.jpg)
2012-2013: Year of intensification of UIP
![Page 26: Conclusions & Recommendations 24 th IEAG March 2012](https://reader033.vdocuments.us/reader033/viewer/2022052414/56649e395503460f94b29ec7/html5/thumbnails/26.jpg)
Recommendations: RI
• State EPRPs and Year of Intensification of UIP plans to be consolidated and operationalized – monitored timelines and milestones
– focus on high risk and migrant populations
– urban and peri-urban populations
• Focus on 239 high risk districts
• Conduct Immunization Weeks in in NE states, UP, Bihar, MP, Rajasthan, Gujarat and Jharkhand
• Priority to ensuring ANMs and MOs are present in HR areas in priority states
![Page 27: Conclusions & Recommendations 24 th IEAG March 2012](https://reader033.vdocuments.us/reader033/viewer/2022052414/56649e395503460f94b29ec7/html5/thumbnails/27.jpg)
Recommendations:
• Surveillance for vaccine preventable diseases should be expanded based on the experience & structure of the AFP surveillance system
• The communications and operational experience of polio eradication should inform other disease control initiatives including measles elimination
![Page 28: Conclusions & Recommendations 24 th IEAG March 2012](https://reader033.vdocuments.us/reader033/viewer/2022052414/56649e395503460f94b29ec7/html5/thumbnails/28.jpg)
Preparing for the endgame
![Page 29: Conclusions & Recommendations 24 th IEAG March 2012](https://reader033.vdocuments.us/reader033/viewer/2022052414/56649e395503460f94b29ec7/html5/thumbnails/29.jpg)
Recent developments
• SAGE Nov 2011: recommended that the endgame strategy be based on phased rather than simultaneous Sabin strain removal
• WHO Executive Board Jan 2012: requested Director-General to develop comprehensive endgame strategy and timeline based on phased Sabin strain removal
• SAGE Apr 2012: may consider an 'early switch' (by Apr 2014), preceded by universal introduction of at least 1 dose of IPV (ID or IM) at DPT3 contact.
![Page 30: Conclusions & Recommendations 24 th IEAG March 2012](https://reader033.vdocuments.us/reader033/viewer/2022052414/56649e395503460f94b29ec7/html5/thumbnails/30.jpg)
IEAG Conclusion: 'Endgame'Following the WHO Executive Board resolution of
January 2012 endorsing eventual replacement of tOPV with bOPV globally, India should start
preparing appropriate policies, esp. on the role of IPV, guided by and considering the global
recommendations of SAGE.
![Page 31: Conclusions & Recommendations 24 th IEAG March 2012](https://reader033.vdocuments.us/reader033/viewer/2022052414/56649e395503460f94b29ec7/html5/thumbnails/31.jpg)
1. The national immunization programme should now begin incorporating into its planning:
(a) an eventual tOPV-bOPV switch globally, potentially as early as April 2014, and
(b) eventual cessation of all remaining bOPV globally at some point in the future (e.g. 2017-18 period).
Recommendations: 'Endgame' planning (1)
![Page 32: Conclusions & Recommendations 24 th IEAG March 2012](https://reader033.vdocuments.us/reader033/viewer/2022052414/56649e395503460f94b29ec7/html5/thumbnails/32.jpg)
2. This planning should include consideration of the introduction, in advance of a tOPV-bOPV switch, of at least one dose of IPV (e.g. at DPT3 contact), to boost population immunity thereby reducing the risk of a type 2 cVDPV emergence & the consequences of a potential cVPDV.
Recommendations: 'Endgame' planning (2)
![Page 33: Conclusions & Recommendations 24 th IEAG March 2012](https://reader033.vdocuments.us/reader033/viewer/2022052414/56649e395503460f94b29ec7/html5/thumbnails/33.jpg)
NID NID
0Jan Mar May Jul Sep Nov Jan Mar May Jul Sep Nov Jan Mar May Jul Sep Nov Jan Mar May
Polio Endgame Strategy-India, Potential Timeline
2011 2012 2013 2014
Last WPV case
Polio certification
IPV intro? NID NID
tOPV NID
Post-switch VDPV type 2 risk mgt.
tOPV-bOPV switch
NID NID NID NID
Certification standard surveillance, improved RI coverage
Modelling, Research, Development
![Page 34: Conclusions & Recommendations 24 th IEAG March 2012](https://reader033.vdocuments.us/reader033/viewer/2022052414/56649e395503460f94b29ec7/html5/thumbnails/34.jpg)
3. convene a small consultation with IEAG members in mid-2012, following the SAGE (April) and World Health Assembly (May), to facilitate national deliberations on the timing and IPV policy options for a tOPV-bOPV switch.
4. begin examining the programmatic and cost implications of adding at least 1 IPV dose to the routine EPI schedule (e.g. at the DPT3 contact) in advance of a global tOPV-bOPV switch.
Recommendations: 'Endgame' planning (3)
![Page 35: Conclusions & Recommendations 24 th IEAG March 2012](https://reader033.vdocuments.us/reader033/viewer/2022052414/56649e395503460f94b29ec7/html5/thumbnails/35.jpg)
5. include an examination of implications (pros/cons) of delivering IPV as a fractional (1/5th) dose intra-dermally (ID) vs. a full dose intramuscularly (IM).
6. consolidate the considerable IPV study data already existing in India, including from licensing trials, to help inform policy options.
7. finalize & start the planned trial to verify the immunogenicity & programmatic feasibility of a 'bOPV + 1 dose of IPV (ID or IM)' routine schedule.
Recommendations: 'Endgame' planning (3)
![Page 36: Conclusions & Recommendations 24 th IEAG March 2012](https://reader033.vdocuments.us/reader033/viewer/2022052414/56649e395503460f94b29ec7/html5/thumbnails/36.jpg)
1. implement the planned research agenda, giving priority to:
(a) complete the mucosal immunity study,
(b) conduct a new seroprevalence survey,
(c) initiate the planned immunogenicity study with bOPV from multiple manufacturers, and
(d) finalize the protocol for the trial to verify immunogenicity, programmatic feasibility of a 'bOPV + 1 dose of IPV (ID or IM)' routine schedule.
Recommendations: Research
![Page 37: Conclusions & Recommendations 24 th IEAG March 2012](https://reader033.vdocuments.us/reader033/viewer/2022052414/56649e395503460f94b29ec7/html5/thumbnails/37.jpg)
Protecting the investment
![Page 38: Conclusions & Recommendations 24 th IEAG March 2012](https://reader033.vdocuments.us/reader033/viewer/2022052414/56649e395503460f94b29ec7/html5/thumbnails/38.jpg)
GoI, partners, & donors
must maintain the human,
material, & financial
infrastructure of polio
eradication until global
certification